[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam].
Real Rodríguez
B
B
Departamento de Pediatría, Hospital Universitario San Carlos, Madrid.
Ruibal
J L
JL
Grande Rodríguez
S
S
Sueiro Pita
B
B
D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D001971:Bromocriptine / Q000627:therapeutic use*; D003620:Dantrolene / Q000627:therapeutic use*; D003975:Diazepam / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D007099:Imipramine / Q000009:adverse effects; D008140:Lorazepam / Q000009:adverse effects; D008297:Male; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D009125:Muscle Relaxants, Central; D001971:Bromocriptine; D003620:Dantrolene; D006220:Haloperidol; D008140:Lorazepam; D007099:Imipramine; D003975:Diazepam